Atlas Trials

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Clinical trial NCT01568294 · COMPLETED

Trial details

NCT number
NCT01568294
Sponsor
Celgene
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2012-04-01
Primary completion
2015-07-08
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.